Morii Yusuke, Senaha Hiromasa, Matsui Shunsuke, Okawa Kazuaki, Tsubaki Masanobu, Matzno Sumio, Shimomura Kazunori, Nishida Shozo
Dept. of Pharmacy, Ikeda City Hospital.
Gan To Kagaku Ryoho. 2022 Jul;49(7):769-773.
Oxaliplatin is a platinum complex antineoplastic agent widely used for chemotherapy of colorectal cancer. However, one of its side effects is hypersensitivity reactions, the incidence of which increases with a cumulative dose, thereby posing a difficulty to continue oxaliplatin use. Our hospital changed the premedication of oxaliplatin in August 2009 and September 2012. We retrospectively investigated the usefulness of these premedication changes. The results showed no significant difference in the incidence of hypersensitivity between the control group(12.1%)and the group receiving H1 and H2-blockers (12.3%); however, the incidence of hypersensitivity was significantly reduced in the group receiving increased dexamethasone based on the number of courses(2.7%). Therefore, our regimen was found to be effective in preventing hypersensitivity reactions to oxaliplatin.
奥沙利铂是一种铂类络合物抗肿瘤药物，广泛用于结直肠癌的化疗。然而，其副作用之一是过敏反应，过敏反应的发生率随累积剂量增加而升高，从而给继续使用奥沙利铂带来困难。我院于2009年8月和2012年9月改变了奥沙利铂的预处理方案。我们回顾性研究了这些预处理方案改变的有效性。结果显示，对照组（12.1%）和接受H1和H2受体阻滞剂组（12.3%）的过敏反应发生率无显著差异；然而，根据疗程增加地塞米松剂量的组中，过敏反应发生率显著降低（2.7%）。因此，我们的方案被发现对预防奥沙利铂过敏反应有效。
